Jeremy Bender, Ph.d., M.b.a.

Biography

Jeremy joined Tizona as COO in July of 2015. In his role, he oversees the company’s finance, operations, alliance, and corporate development activities. Prior to Tizona, Jeremy was Chief Business Officer of Sutro Biopharma, where he was responsible for business development, alliance and project management, external communications, and intellectual property strategy. During his time at Sutro, he completed partnering transactions with Celgene Corporation and EMD Serono, providing more than $150M in non-dilutive capital. He joined Sutro from Allos Therapeutics following the company’s acquisition by Spectrum Pharmaceuticals in September 2012. As Vice President of Corporate Development at Allos, Jeremy completed multiple licensing equity financing transactions and contributed to the development and commercialization of Folotyn, the first product approved in the U.S. for the treatment of peripheral T-cell lymphoma. He began his career as a strategy consultant in the Life Sciences practice at the Boston Consulting Group. Jeremy received his undergraduate degree in Biological Sciences from Stanford University and his Ph.D. in Microbiology & Immunology from the University of Colorado, where he worked on peripheral T-cell selection in the labs of Philippa Marrack and John Kappler. Jeremy also received an MBA from the MIT Sloan School of Management.

Research Interest

Jeremy joined Tizona as COO in July of 2015. In his role, he oversees the company’s finance, operations, alliance, and corporate development activities. Prior to Tizona, Jeremy was Chief Business Officer of Sutro Biopharma, where he was responsible for business development, alliance and project management, external communications, and intellectual property strategy. During his time at Sutro, he completed partnering transactions with Celgene Corporation and EMD Serono, providing more than $150M in non-dilutive capital. He joined Sutro from Allos Therapeutics following the company’s acquisition by Spectrum Pharmaceuticals in September 2012. As Vice President of Corporate Development at Allos, Jeremy completed multiple licensing equity financing transactions and contributed to the development and commercialization of Folotyn, the first product approved in the U.S. for the treatment of peripheral T-cell lymphoma. He began his career as a strategy consultant in the Life Sciences practice at the Boston Consulting Group. Jeremy received his undergraduate degree in Biological Sciences from Stanford University and his Ph.D. in Microbiology & Immunology from the University of Colorado, where he worked on peripheral T-cell selection in the labs of Philippa Marrack and John Kappler. Jeremy also received an MBA from the MIT Sloan School of Management.